Patents by Inventor Chengde Wu

Chengde Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRD4 INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20220185820
    Abstract: Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases.
    Type: Application
    Filed: March 23, 2020
    Publication date: June 16, 2022
    Inventors: Chunli SHEN, Yong LIU, Huanyu BIAN, Chengde WU, Jiahu WU
  • COMPOUNDS HAVING BOTH EFFECTS OF BET BROMODOMAIN PROTEIN INHIBITION AND PD-L1 GENE REGULATION
    Publication number: 20220177490
    Abstract: Compounds having both BET bromodomain protein inhibitory activity and PD-L1 gene expression regulation, and use thereof in preparing medicaments for treating tumor diseases related to BET bromodomain protein inhibition and PD-L1 gene expression. Specifically disclosed are a compound as shown in formula (1), and an isomer and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Chunli SHEN, Yuchuan ZHU, Ting WANG, Chengde WU, Shuhui CHEN
  • GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220153772
    Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.
    Type: Application
    Filed: March 30, 2020
    Publication date: May 19, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Yi LI, Tao YU, Qinghua MAO, Chengde WU, Shuhui CHEN
  • Diarylthiohydantoin compound as androgen receptor antagonist
    Patent number: 11332465
    Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: May 17, 2022
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Chunli Shen, Chengde Wu, Shenglin Chen, Shuhui Chen, Xiquan Zhang, Xin Tian
  • Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof
    Publication number: 20220135588
    Abstract: A novel five-membered heteroaromatic imidazole compound and use thereof is disclosed herein. Specifically, disclosed is a compound as shown in formula (III) or a pharmaceutically acceptable salt thereof. Also disclosed is a method for treating a disease related to GLP-1 receptor such as type II diabetes.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Inventors: Tao YU, Lu GAN, Chengde WU, Shuhui CHEN
  • Thienodiazepine derivatives and application thereof
    Patent number: 11312726
    Abstract: The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 26, 2022
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Chunli Shen, Chengde Wu, Yong Liu, Zhen Gong, Jian Li, Shuhui Chen
  • PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR
    Publication number: 20220112217
    Abstract: A series of pyrazolopyrimidine derivatives can be used in preparing a medicament for treating a disease related to PI3K. For example, a compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof are effective in treating a disease related to P13K.
    Type: Application
    Filed: August 21, 2019
    Publication date: April 14, 2022
    Inventors: Chengde WU, Jingjie HUANG, Tao YU, Jie LI, Zhen GONG, Jian LI, Shuhui CHEN
  • Crystal form as ASK1 inhibitor and preparation method and application thereof
    Publication number: 20210269441
    Abstract: Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.
    Type: Application
    Filed: July 19, 2019
    Publication date: September 2, 2021
    Inventors: Shengbin ZHANG, Ning LI, Tao YU, Yusheng FU, Jiahu WU, Chengde WU
  • Pyridine derivative as ASK1 inhibitor and preparation method and use thereof
    Patent number: 11040968
    Abstract: Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 22, 2021
    Inventors: Chengde Wu, Tao Yu, Ning Li, Shuhui Chen
  • Coumarin-like cyclic compound as MEK inhibitor and use thereof
    Patent number: 11021486
    Abstract: Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 1, 2021
    Assignees: CSTONE PHARMACEUTICALS, CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.
    Inventors: Qinghua Mao, Chengde Wu, Yong Huang, Zhen Gong, Jian Li, Shuhui Chen
  • THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF
    Publication number: 20210017190
    Abstract: The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 21, 2021
    Inventors: Chunli SHEN, Chengde WU, Yong LIU, Zhen GONG, Jian LI, Shuhui CHEN
  • SGLTS inhibitor and application thereof
    Patent number: 10822365
    Abstract: A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: November 3, 2020
    Inventors: Chengde Wu, Qinghua Mao, Yi Li, Tao Yu, Shuhui Chen
  • SGLTS INHIBITOR AND APPLICATION THEREOF
    Publication number: 20200331950
    Abstract: A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Inventors: CHENGDE WU, QINGHUA MAO, YI LI, TAO YU, SHUHUI CHEN
  • Quinazolinone Compound and Application Thereof
    Publication number: 20200317660
    Abstract: The present invention relates to a series of quinazolinone compounds and applications thereof as PI3K? inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 12, 2018
    Publication date: October 8, 2020
    Inventors: Chengde WU, Jingjie HUANG, Tao YU, Jiaqiang DONG, Tie-Lin WANG, Jie LI, Jian LI, Shuhui CHEN
  • ASK1 inhibitor and preparation method and use thereof
    Patent number: 10787435
    Abstract: The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 29, 2020
    Assignee: Fuijan Cosunter Pharmaceutical Co. Ltd.
    Inventors: Chengde Wu, Tao Yu, Ning Li, Shuhui Chen
  • DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
    Publication number: 20200277290
    Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.
    Type: Application
    Filed: August 7, 2018
    Publication date: September 3, 2020
    Inventors: Chunli SHEN, Chengde WU, Shenglin CHEN, Shuhui CHEN, Xiquan ZHANG, Xin TIAN
  • BTK inhibitor
    Patent number: 10662174
    Abstract: Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 26, 2020
    Assignee: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC.
    Inventors: Xuehai Wang, Chengde Wu, Yong Xu, Chunli Shen, Li'e Li, Guoping Hu, Yang Yue, Jian Li, Diliang Guo, Nengyang Shi, Lu Huang, Shuhui Chen, Ronghua Tu, Zhongwen Yang, Xuwen Zhang, Qiang Xiao, Hua Tian, Yanping Yu, Hailiang Chen, Wenjie Sun, Zhenyu He, Jie Shen, Jing Yang, Jing Tang, Wen Zhou, Jing Yu, Yi Zhang, Quan Liu
  • COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF
    Publication number: 20200148695
    Abstract: Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 14, 2020
    Applicants: CSTONE PHARMACEUTICALS, CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.
    Inventors: Qinghua MAO, Chengde WU, Yong HUANG, Zhen GONG, Jian LI, Shuhui CHEN
  • PYRIDINE DERIVATIVE AS ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20200031823
    Abstract: Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
    Type: Application
    Filed: January 22, 2018
    Publication date: January 30, 2020
    Applicant: FUJUAN COSUNTER PHARMACEUTICAL CO., LTD.
    Inventors: Chengde WU, Tao YU, Ning LI, Shuhui CHEN
  • Piperidine compounds as PCSK9 inhibitors
    Patent number: 10513514
    Abstract: One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: December 24, 2019
    Assignee: SHENZHEN SALUBRIS PHARM CO LTD.
    Inventors: Chengde Wu, Jie Yan, Wenjie Xu, Tao Yu, Ning Li, Shuhui Chen